All News
Filter News
Found 153 articles
-
Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs
5/3/2022
Aligos Therapeutics, Inc. today announced that the company will present three posters highlighting data from three of the company’s programs in chronic hepatitis B (CHB) at the European Association for the Study of the Liver’s International Liver Congress 2022.
-
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
4/27/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s first quarter 2022 financial results on Wednesday, May 4, 2022 after the close of U.S. financial markets.
-
Stephane Bancel, the chief executive of Moderna, has likened the need for booster vaccine doses to the way Apple releases new smartphones every year.
-
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19
4/4/2022
Aligos Therapeutics, Inc. today announced that it has selected ALG-097558, a broad spectrum coronavirus protease inhibitor, as its drug candidate to move forward into development.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Aligos Therapeutics, headquartered in South San Francisco, halted the development of ALG-020572, which was being developed in patients with chronic hepatitis B (CHB).
-
Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
3/22/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has discontinued development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB).
-
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
3/10/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced its financial results for the fourth quarter and full year 2021 and provided an overview of recent business highlights.
-
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
3/2/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 after the close of U.S. financial markets.
-
Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/3/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present in a fireside chat format at the virtual 11th Annual SVB Leerink Global Healthcare Conference.
-
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
1/26/2022
Aligos Therapeutics, Inc. today announced that he first chronic hepatitis B (CHB) patient has been dosed in the multiple ascending dose (MAD) portion of Study ALG-020572-401 (NCT05001022) which is evaluating antisense oligonucleotide (ASO) ALG-020572.
-
Sixty-three percent of patients met the primary endpoint of a 2-point or greater improvement in disease severity without worsening of fibrosis.
-
Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH
1/11/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has expanded its ongoing collaboration agreement with Merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH).
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133Phase 1 data at projected efficacious dose (400 mg) indicate insufficient activity against hepatitis B virus to justify further development
1/6/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has halted further development of its STOPS™ drug candidate, ALG-010133, in development to address chronic hepatitis B (CHB).
-
Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
12/21/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the 40th Annual J.P. Morgan Healthcare Conference.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study
12/9/2021
Aligos Therapeutics, Inc. today announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 (NCT05090111).
-
Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021
12/7/2021
New data from HBeAg-positive patients receiving 100 mg of ALG-000184 demonstrates similar PK and potent antiviral activity to previously reported data for HBeAg-negative patients.
-
Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases
11/23/2021
Vipergen announced today the signing of a multi-target drug discovery agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS).